P2Y\textsubscript{12} inhibitors for acute coronary syndromes: current perspectives

This article was published in the following Dove Press journal:
Research Reports in Clinical Cardiology
9 October 2015
Number of times this article has been viewed

Abstract: Antiplatelet therapies are a cornerstone for the management of acute coronary syndromes (ACSs), based largely on the prominent role that platelet activation and aggregation has on the pathophysiology of the disease. Dual-antiplatelet therapy involving an oral P2Y\textsubscript{12} inhibitor plus aspirin is now considered standard of care for treating ACS. While clopidogrel has enjoyed nearly exclusive use as the P2Y\textsubscript{12} inhibitor of choice for many years, the more powerful P2Y\textsubscript{12} inhibitors prasugrel and ticagrelor have recently challenged clopidogrel as the preferred antiplatelet therapy for treating ACS. Both prasugrel and ticagrelor have proven to be superior to clopidogrel in reducing cardiovascular events in large clinical trials, albeit at the risk of increased bleeding. With the availability of these newer more potent agents, tailoring P2Y\textsubscript{12} inhibition to be more patient specific becomes an intriguing possibility. Factors such as type of ACS presentation, patient comorbidities, use of concomitant medications, platelet reactivity, genetic predisposition, and cost should all be considered. In addition to oral agents, intravenous P2Y\textsubscript{12} inhibition with cangrelor offers the advantage of quick onset and offset of action, but its clinical role is yet to be defined. Optimal medical and mechanical treatment of ACS hinges on suppressing platelet-related pathways, and P2Y\textsubscript{12} inhibition plays a key role. As our understanding of ACS continues to evolve, there remains much to learn with respect to optimizing the use of these powerful drugs to most effectively help achieve the best clinical outcomes.

Keywords: P2Y\textsubscript{12} inhibitors, acute coronary syndrome, ticagrelor, prasugrel, clopidogrel

Introduction

The predominant pathophysiological cause of acute coronary syndromes (ACSs) is atherosclerotic plaque rupture and subsequent arterial thrombosis. Platelets are the principal components of an arterial thrombus, and their rapid aggregation at the site of arterial damage leads to a constellation of events further contributing to thrombus progression and growth.\textsuperscript{1,2} Drugs that inhibit platelet aggregation would therefore be of theoretical benefit for treating ACS and clinical trials have indeed proven this to be the case. Clinical practice guidelines now state that oral antiplatelet therapies are foundational treatments for ACSs.\textsuperscript{3-6} The benefits of aspirin for treating ACS were established in 1988 when the Second International Study of Infarct Survival trial demonstrated that 160 mg/day of aspirin reduced vascular death, both alone and in combination with streptokinase, in patients with a suspected myocardial infarction (MI).\textsuperscript{7} Aspirin is now considered first-line therapy for all patients with ACS.\textsuperscript{3-6} The landscape changed with the publication of the CURE trial in 2001, which demonstrated that adding clopidogrel to aspirin reduced major adverse cardiovascular events by 20%
compared to aspirin alone in patients suffering from an ACS without ST-segment elevation. Since then, other trials have supported the benefits of dual-antiplatelet therapy (DAPT) in various ACS settings.\textsuperscript{3–12}

Despite the benefits of clopidogrel, it is not universally effective, which may in part be due to genetic variations in response. In addition, the magnitude of antiplatelet effect is moderate and it can take up to 8 hours to reach maximal effect after a 600 mg loading dose. These limitations of clopidogrel have led to the development and approval of alternative agents that also target the P2Y$_{12}$ receptor. Prasugrel and ticagrelor, like clopidogrel, block the binding of adenosine diphosphate to the P2Y$_{12}$ platelet receptor, thereby interfering with platelet activation and aggregation. However, both prasugrel and ticagrelor yield faster and more pronounced inhibition of platelet aggregation compared to clopidogrel (Table 1). In addition, ticagrelor does not need to be metabolically activated and prasugrel requires only one metabolic step for activation compared to two for clopidogrel. This reduces the potential for variations in response with prasugrel and ticagrelor compared to clopidogrel due to fewer potential drug interactions and lesser influence of genetic variability of drug-metabolizing enzyme activity.

In addition, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 and the study of Platelet Inhibition and Patient Outcomes (PLATO) proved prasugrel and ticagrelor, respectively, to be superior to clopidogrel in terms of reducing ischemic events, albeit with a higher risk of bleeding.\textsuperscript{22,23}

Cangrelor is an intravenously administered investigational P2Y$_{12}$ inhibitor with a very short half-life (3–6 minutes) and a rapid onset and offset of effect, with the platelet function normalizing within 60 minutes of drug discontinuation.\textsuperscript{24,25} As such, it is only being investigated for use in the acute setting. The CHAMPION studies comprise the major clinical trial data evaluating cangrelor for ACS treatment. CHAMPION PCI (n=8,877) and CHAMPION PLATFORM (n=5,362) were both placebo-controlled trials that compared cangrelor to a 600 mg loading dose of clopidogrel in ACS patients scheduled to undergo PCI.\textsuperscript{24,25} CHAMPION PCI administered the clopidogrel load at the start of PCI, whereas CHAMPION PLATFORM administered the clopidogrel load at the end of the procedure. The primary end point of death, MI, or ischemia-driven revascularization at 48 hours was comparable between the two groups in both studies. However, MI was the most frequently occurring end point in both of these studies, which is often difficult to adjudicate periprocedurally due to rising levels of baseline cardiac biomarkers associated with the index event. When the pooled results of the CHAMPION PCI and CHAMPION PLATFORM trials were analyzed in the non-STEMI population using the universal (vs protocol) definition of MI, cangrelor reduced the risk of the primary end point by 18% compared to clopidogrel (P=0.018).\textsuperscript{26,27} The CHAMPION PHOENIX trial more carefully defined periprocedural MI in comparing cangrelor to clopidogrel in 11,145 patients undergoing PCI (57% stable angina, 43% ACS) who had not received an oral P2Y$_{12}$ inhibitor within 7 days before randomization.\textsuperscript{28} In this double-blind, placebo-controlled study, cangrelor reduced the primary end point of death, MI, ischemia-driven revascularization, or stent thrombosis at 48 hours compared to clopidogrel (4.7% vs 5.9%, P=0.005), with most of the benefit occurring through a reduction in MI and stent thrombosis. In addition, severe bleeding was not significantly increased with cangrelor. However, about 25% of patients in this trial received a 300 mg versus 600 mg loading dose of clopidogrel and 37% of patients in the clopidogrel group received the drug during or after PCI, raising concerns as to whether or not a sufficient antiplatelet effect was present during PCI in these patients.\textsuperscript{29} There are also concerns regarding, even with the attention given to defining MI, whether or not this study was able to accurately

<table>
<thead>
<tr>
<th>Drug</th>
<th>P2Y$_{12}$ Receptor binding</th>
<th>Steady-state IPA*</th>
<th>Maximum IPA*</th>
<th>Time to maximum IPA*</th>
<th>Metabolism required for effect?</th>
<th>Offset of action*</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clopidogrel</td>
<td>Irreversible</td>
<td>40%–62%</td>
<td>$\leq$50%</td>
<td>4–8 hrs$^t$</td>
<td>Yes, two-step P450 activation</td>
<td>5–7 days</td>
<td>Oral, once daily</td>
</tr>
<tr>
<td>Prasugrel</td>
<td>Irreversible</td>
<td>70%</td>
<td>75–80%</td>
<td>2–4 hrs</td>
<td>Yes, one-step P450 activation</td>
<td>5–7 days</td>
<td>Oral, once daily</td>
</tr>
<tr>
<td>Ticagrelor</td>
<td>Reversible</td>
<td>80%–90%</td>
<td>80–88%</td>
<td>2–4 hrs</td>
<td>No</td>
<td>3–5 days</td>
<td>Oral, twice daily</td>
</tr>
<tr>
<td>Cangrelor</td>
<td>Reversible</td>
<td>95%–100%</td>
<td>95%–100%</td>
<td>2 min</td>
<td>No</td>
<td>60–90 min</td>
<td>Intravenous infusion</td>
</tr>
</tbody>
</table>

Notes: *After a loading dose (bolus dose + infusion for cangrelor); †based on return of platelet aggregation and/or bleeding time to baseline values; ‡600 mg loading dose. Based on data from 10–13.}

Abbreviations: IPA, inhibition of platelet aggregation; hrs, hours; min, minutes.
define periprocedural MI according to the universal definition, which requires at least two serum cardiac biomarker samples taken 6 hours apart in patients with elevated biomarkers before PCI; the median time from hospital admission to PCI was 4.4 hours in CHAMPION PHOENIX.26,29 Cangrelor is currently indicated as an adjunct to PCI for reducing the risk of periprocedural MI, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y<sub>12</sub> inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.30 Cangrelor has also shown promise as a bridging agent in patients requiring surgery. In a double-blind, placebo-controlled study of 210 patients who required discontinuation of P2Y<sub>12</sub> inhibitor for coronary artery bypass grafting (CABG) surgery, cangrelor provided sustained inhibition of platelet function throughout the preoperative period without an increase in major bleeds, although there were numerically more minor bleeding episodes with cangrelor.31 However, this was not a clinical outcome study and the results should be interpreted with that in mind.

So while DAPT for ACS has predominantly included aspirin and clopidogrel, the clinician currently has the option of choosing from among three different oral P2Y<sub>12</sub> inhibitors for this indication. In addition, the role of intravenous ultrafast acting P2Y<sub>12</sub> inhibition with cangrelor holds promise, but still needs to be better defined and is not the focus of this review. This paper discusses different considerations the clinician, as well as health care system, must weigh when selecting the most appropriate oral P2Y<sub>12</sub> inhibitor for each individual patient presenting with an ACS.

**Type of ACS and treatment strategy**

**ST-elevation myocardial infarction**

Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for treating ST-elevation MI (STEMI), and clopidogrel, prasugrel, and ticagrelor all have evidence supporting their use in this scenario. The use and benefits of DAPT for patients undergoing PPCI in STEMI were established prior to the more widespread use of clopidogrel following the CURE trial in 2001. The ISAR and STARS trials published in 1997 and 1998, respectively, demonstrated the superiority of ticlopidine plus aspirin compared to both aspirin alone and aspirin plus warfarin in post-stent patients.22,33 The unfavorable hematologic side effect profile of ticlopidine has led to it being used only very rarely in contemporary practice, and clopidogrel has been shown to be an equally efficacious yet safer alternative.34 Consequently, DAPT with clopidogrel and aspirin has been considered the standard of care for many years for patients undergoing PPCI. This said, questions about the optimal dosing of aspirin and clopidogrel led to the conduct of the CURRENT-OASIS 7 trial involving 25,086 patients undergoing an invasive treatment strategy for ACS (29% STEMI, 71% unstable angina [UA] or non-STEMI).8 In this trial, doubling the dose of clopidogrel (600 mg loading dose followed by 150 mg daily for 6 days, then 75 mg daily) or using higher dose aspirin (300–325 mg daily) offered no efficacy advantage in reducing the primary end point of cardiovascular death, MI, or stroke at 30 days compared to standard-dose clopidogrel (300 mg load followed by 75 mg daily) or lower dose aspirin (75–100 mg daily). However, double-dose clopidogrel increased the incidence of major bleeding compared to standard-dose clopidogrel (2.5% vs 2.0%; hazard ratio [HR] 1.24, 95% confidence interval [CI] 1.05–1.46; \( P = 0.01 \)). In addition, a prespecified subgroup analysis of patients who underwent PCI for ACS \((n=17,263)\) demonstrated that double-dose clopidogrel reduced the rate of the primary outcome by 14% \((P=0.039)\) as well as the rate of definite stent thrombosis by 46% \((P=0.0001)\), albeit with a 41% increase in the rate of major bleeding \((P=0.009)\).12 The data supporting the use of prasugrel for STEMI emanate from the TRITON-TIMI 38 trial that enrolled 13,608 patients with ACS scheduled to undergo PCI.22,35 In this study overall, prasugrel plus aspirin was more effective than clopidogrel plus aspirin at reducing the incidence of the primary end point of cardiovascular death, nonfatal MI, or nonfatal stroke (9.9% vs 12.1%; HR 0.81, 95% CI 0.73–0.90; \( P < 0.001 \)), albeit with an increase in the risk of non-CABG-related major bleeds (2.4% vs 1.8%; HR 1.32, 95% CI 1.03–1.68; \( P = 0.03 \)).22 All-cause mortality did not differ between prasugrel and clopidogrel, and there was no increase in the risk of intracranial hemorrhage with prasugrel except in those patients with a history of a cerebrovascular event. Overall, the clinical benefits of prasugrel were independent of ACS type (ie, UA/non-STEMI or STEMI). Data from the prespecified cohort of patients who presented with STEMI and underwent PPCI (26% of patients) demonstrated a 21% reduction in the primary end point compared to clopidogrel at 15 months \((P=0.02)\).22,35 Interestingly, non-CABG-related major bleeding was not increased with prasugrel in the STEMI cohort (1.0% prasugrel vs 1.3% clopidogrel; \( P = 0.34 \)).35

The landmark trial that assessed the safety and efficacy of ticagrelor was the PLATO trial.21 Overall, PLATO demonstrated that ticagrelor plus aspirin reduced the primary end point of vascular death, MI, or stroke by 16% compared to...
clopidogrel plus aspirin ($P<0.001$), although non-CABG-related major bleeding was greater with ticagrelor compared to clopidogrel (19% increase in risk using study-defined criteria; 25% increase in risk using TIMI-defined criteria; $P=0.03$ for both). There was a 22% risk reduction in all-cause mortality with ticagrelor treatment (4.5% vs 5.9%; $P<0.001$), but ticagrelor also increased the risk of intracranial hemorrhage by 87% (0.3% vs 0.2%; $P=0.06$). The STEMI cohort represented 38% of the entire study cohort, and this subgroup experienced efficacy similar to that of the overall population: a 13% risk reduction in the primary end point with ticagrelor ($P=0.07$) and an 18% reduction in all-cause mortality ($P=0.05$). Non-CABG-related major bleeding was not significantly different between ticagrelor and clopidogrel in this subgroup. An additional analysis showed that the reduction in MI seen with ticagrelor occurred primarily in patients who were admitted with STEMI, while those admitted with non-STEMI experienced a reduction in cardiovascular mortality but not MI.

Although PPCI is the preferred treatment for STEMI, a good proportion of patients still receive fibrinolytic therapy for reperfusion. Among these patients, the strongest data support the use of clopidogrel. The CLARITY-TIMI 28 trial demonstrated that adding clopidogrel (300 mg load followed by 75 mg daily) to aspirin and fibrinolytic therapy was superior to placebo (with aspirin and fibrinolytic) in reducing the composite primary end point of an occluded infarct-related artery on angiography or death or recurrent MI before angiography (HR 0.64, 95% CI 0.53–0.76; $P<0.001$) in 3,491 patients being treated for ST-elevation MI. At 30 days, clopidogrel therapy reduced the composite end point of cardiovascular death, recurrent MI, or recurrent ischemia leading to urgent revascularization by 20% ($P=0.03$). The COMMIT trial randomized 45,852 patients with acute MI (87% with ST-elevation; 6% with bundle branch block) to receive either clopidogrel or placebo in addition to aspirin therapy. Patients undergoing primary PCI were excluded, and fibrinolytic therapy was administered to 54% of patients at some time before or after randomization. Overall, clopidogrel reduced the primary composite outcome of death, reinfarction or stroke by 9% (95% CI 0.86–0.97; $P=0.002$) and reduced death alone by 7% (95% CI 0.87–0.99; $P=0.03$) compared to placebo with no significant excess risk of bleeding. These benefits were present both in patients who did and did not receive fibrinolytic therapy, although numerically the benefit was more pronounced in patients who received fibrinolytic therapy (11% risk reduction in the primary end point with fibrinolytic therapy vs 7% without fibrinolytic therapy; $P=0.4$).

**Non-ST-elevation ACS**

Current clinical practice guidelines for the management of non-ST-elevation ACS divide disease management into two general treatment approaches: 1) an early invasive strategy (ie, coronary angiography with intent to perform immediate revascularization) and 2) an ischemia-guided strategy (ie, coronary angiography only if refractory or recurrent symptoms despite medical treatment or hemodynamic instability). Clopidogrel has been studied using both of these management approaches. The landmark CURE study compared clopidogrel plus aspirin to placebo plus aspirin in 12,562 patients suffering from non-ST-elevation ACS. Overall, clopidogrel plus aspirin was more beneficial than aspirin alone at reducing the composite end point of cardiovascular death, nonfatal MI, or stroke (HR 0.80, 95% CI 0.72–0.90; $P<0.001$) with a 38% increase in risk for major bleeding ($P=0.001$). The benefits of clopidogrel were independent of admitting diagnosis (75% of patients had UA, 25% non-STEMI) or whether or not patients were revascularized with PCI after randomization. The CURE trial employed primarily an ischemia-guided strategy, with PCI being performed at the discretion of the local investigator. Forty-four percent of patients underwent coronary angiography after randomization and 21% underwent PCI (14% during initial hospitalization, 7% after discharge). A median of 6 days had passed before PCI was performed in those receiving PCI during the initial hospitalization. For patients undergoing an early invasive management strategy for non-ST-elevation ACS, the results from the CURRENT-OASIS 7 trial can be applied to clopidogrel treatment. For non-ST-elevation ACS with an early invasive approach, both prasugrel and ticagrelor have evidence to support their use. In TRITON-TIMI 38 trial, all patients underwent PCI and an early invasive treatment strategy. Three-quarters of the cohort were patients with UA or non-STEMI and showed similar clinical benefits of prasugrel over clopidogrel independent of ACS type. Similarly in PLATO, the vast majority of patients were enrolled with UA or non-STEMI although only 72% underwent planned invasive treatment. The benefits of ticagrelor over clopidogrel were independent of whether an early invasive or ischemia-guided strategy was employed. A subgroup analysis from PLATO demonstrated that patients admitted with MI (either STEMI or non-STEMI) had significant reductions in major adverse
cardiovascular events with ticagrelor plus aspirin versus clopidogrel plus aspirin, whereas those admitted with UA did not (HR 0.96, 95% CI 0.75–1.22). However, the study was underpowered for patients with UA, the test for interaction by clinical presentation of ACS was negative (P=0.41), and there is no biologically plausible explanation for this purported lack of benefit in UA patients. As such, patients with UA are believed to be appropriate candidates for ticagrelor therapy.

For patients with non-ST-elevation ACS undergoing an ischemia-guided strategy (PCI optional), it is important to note that only ticagrelor (not prasugrel) is supported by evidence of benefit over clopidogrel. Twenty-eight percent of patients in the PLATO trial underwent an ischemia-guided treatment strategy, and ticagrelor was shown to be more beneficial than clopidogrel in that group. TRITON-TIMI 38 did not enroll patients undergoing an ischemia-guided strategy. Consequently, the TRILOGY-ACS trial was conducted in 7,243 patients with non-ST-elevation ACS who were not planned to undergo revascularization in order to compare the efficacy and safety of prasugrel plus aspirin to clopidogrel plus aspirin as part of medical therapy. After a median follow-up of 17 months, there was no difference in either the primary efficacy endpoint of cardiovascular death, MI, or stroke or bleeding rates between prasugrel and clopidogrel.

In summary, the clinical trial results as well as clinical practice guidelines support the use of clopidogrel, prasugrel, or ticagrelor for all types of ACS (Figure 1). Landmark trial data are reviewed in Table 2. Clopidogrel is efficacious for STEMI treatment regardless of whether PPCI or fibrinolysis is the chosen treatment approach. Similarly, clopidogrel is efficacious for non-ST-elevation ACS treatment regardless of whether an early invasive or ischemia-driven management strategy is selected. Prasugrel has not been adequately studied in patients receiving a fibrinolytic drug for STEMI and has not shown superior efficacy over clopidogrel for non-ST-elevation ACS undergoing an ischemia-guided strategy.

Figure 1 Guideline-based recommendations for oral P2Y12 selection for acute coronary syndromes.

Notes: 1Initial ischemia-guided strategy means that coronary angiography with possible PCI is not performed initially, but rather in response to refractory or recurrent ischemia following initial treatment; 2do not give prasugrel to a patient with a prior history of stroke and/or TIA or age ≥75 years. Prasugrel is only preferred over clopidogrel for patients not at high risk for bleeding; 3alternative per European Society of Cardiology guidelines, which prefer either prasugrel or ticagrelor unless these drugs are contraindicated or not available. American College of Cardiology guidelines give all three P2Y12 inhibitors equal support for primary PCI. Data from references. Shaded boxes represent treatment selection.

Abbreviations: PCI, percutaneous coronary intervention; MI, myocardial infarction; TIA, transient ischemic attack.
<table>
<thead>
<tr>
<th>Clinical trial</th>
<th>Treatments* and primary end points</th>
<th>Primary end point results</th>
<th>ST-elevation vs non-ST-elevation ACS</th>
<th>PCI vs no PCI/revascularization</th>
</tr>
</thead>
</table>
| **CURE**<sup>12</sup> | Clopidogrel vs placebo  
**Efficacy:** CV death, MI, or stroke at 12 months  
**Safety:** major bleeding | Entire study population: n=12,562 with ACS  
Efficacy: 9.3% clopidogrel vs 11.4% placebo; P<0.001  
Safety: 3.7% clopidogrel vs 2.7% placebo; P=0.001 | Not applicable; only non-ST-elevation ACS studied | Efficacy: PCI (n=2,658): 4.5% clopidogrel vs 6.4% placebo; P=0.03; no revascularization (n=7,985): 8.1% clopidogrel vs 10.0% placebo; P<0.05  
Safety: 1.6% clopidogrel vs 1.4% placebo (P=0.69) in PCI subgroup; not reported for no revascularization subgroup |
| **CURRENT-OASIS 7<sup>8,12</sup>** | Double-dose clopidogrel for 6 days followed by standard-dose clopidogrel vs standard-dose clopidogrel  
**Efficacy:** CV death, MI, or stroke at 30 days  
**Safety:** major bleeding | Entire study population: n=25,086 with ACS  
Efficacy: 4.2% double dose vs 4.4% standard dose; P=0.30  
Safety: 2.5% double dose vs 2.0% standard dose; P=0.01 | Efficacy: STEMI (n=7,327): 4.7% double dose vs 5.2% standard dose; P=0.32; non-ST-elevation ACS (n=17,759): 4.0% double dose vs 4.1% standard dose; P=0.58  
Safety: not reported by type of ACS | Efficacy: PCI — overall (n=17,263): 3.9% double dose vs 4.5% standard dose; P=0.039; STEMI (n=6,364): 4.2% vs 5.0%; P=0.117; non-ST-elevation ACS (n=10,899): 3.6% vs 4.2%; P=0.167; no PCI (n=7,823): 4.9% double dose vs 4.3% standard dose; P=0.22  
Safety: 1.6% double dose vs 1.1% standard dose (P=0.009) in the PCI subgroup; not reported for the no PCI subgroup |
| **CLARITY-TIMI 28<sup>10</sup>** | Clopidogrel vs placebo  
**Efficacy:** occluded infarct-related artery on angiography or death or recurrent MI before angiography  
**Safety:** major bleeding | Entire study population: n=3,491 with STEMI  
Efficacy: 15.0% clopidogrel vs 21.7% placebo; P<0.001  
Safety: 1.3% clopidogrel vs 1.1% placebo; P=0.64 | Not applicable; only STEMI studied | Not applicable; all patients were scheduled to receive fibrinolytic therapy |
| **COMMIT**<sup>11</sup> | Clopidogrel vs placebo  
**Efficacy:** 1) death, reinfarction, or stroke at 28 days and 2) all-cause mortality  
**Safety:** fatal, transfused, or cerebral bleeds | Entire study population: n=45,852 with acute MI  
Efficacy: 1) 9.2% clopidogrel vs 10.1% placebo; P=0.002; 2) 7.5% clopidogrel vs 8.1% placebo; P=0.03  
Safety: 0.58% clopidogrel vs 0.55% placebo; P=0.59 | Efficacy: STEMI (n=39,755): 8.8% clopidogrel vs 9.8% placebo; P=0.05; ST depression MI (n=3,169): 6.2% clopidogrel vs 7.0% placebo; P=NS; bundle branch block MI (n=2,928): 17.9% clopidogrel vs 17.4% placebo; P=NS  
Safety: subgroup data not reported | Not applicable; primary PCI patients excluded |
| **TRITON-TIMI 38<sup>22,35</sup>** | Prasugrel vs clopidogrel  
**Efficacy:** CV death, MI, or stroke at 15 months  
**Safety:** major bleeding (non-CABG) | Entire study population: n=13,608 with ACS  
Efficacy: 9.9% prasugrel vs 12.1% clopidogrel; P=0.001  
Safety: 2.4% prasugrel vs 1.8% clopidogrel; P=0.03 | Efficacy: STEMI (n=3,534): 10.0% prasugrel vs 12.4% clopidogrel; P=0.02; non-ST-elevation ACS (n=10,074): 9.9% prasugrel vs 12.1% clopidogrel; P=0.002  
Safety: 1.0% prasugrel vs 1.3% clopidogrel in the STEMI population (P=0.34); not reported in the non-ST-elevation ACS cohort | Not applicable; all patients were scheduled to undergo PCI |
| **TRILOGY-ACS**<sup>41</sup> | Prasugrel vs clopidogrel  
**Efficacy:** CV death, MI, or stroke at 30 months (median 17 months)  
**Safety:** severe or life-threatening (non-CABG) bleeding | Entire study population: n=7,243 with ACS  
Efficacy: 18.7% prasugrel vs 20.3% clopidogrel; P=0.45  
Safety: 1.1% prasugrel vs 1.0% clopidogrel; P=0.53 | Not applicable; only non-ST-elevation ACS studied | Not applicable; all patients were selected to undergo a noninvasive (ie, medical management) strategy |
Ticagrelor vs clopidogrel

PLATO 3,36,39-40

Efficacy: vascular death, MI, or stroke at 12 months

n=18,624 with ACS

Efficacy: 9.8% ticagrelor vs 11.7% clopidogrel; P=0.001

Safety: 11.6% ticagrelor vs 11.2% clopidogrel; P=0.43

Efficacy: STEMI or new left bundle branch block

(n=7,544): 9.4% ticagrelor vs 10.8% clopidogrel; P=0.07; all non-ST-elevation ACS (n=1,080):

10.0% ticagrelor vs 12.3% clopidogrel; P=0.001; unstable angina (n=3,112): 8.6% ticagrelor vs

9.1% clopidogrel; P=NS; non-STEMI (n=7,955): 11.4% ticagrelor vs 13.9% clopidogrel; P=0.05

Safety: STEMI or left bundle branch block: 9.0% ticagrelor vs 9.2% clopidogrel; P=0.07; all non-

ST-elevation ACS: 13.4% ticagrelor vs 12.6% clopidogrel; P=0.26; unstable angina: 10.4% ticagrelor vs

9.9% clopidogrel; P=NS; non-STEMI: 14.7% ticagrelor vs 14.3% clopidogrel; P=NS

Efficacy: invasive treatment approach – overall

(n=13,408): 9.0% ticagrelor vs 10.7% clopidogrel; P=0.0025; STEMI (n=6,575): 8.1% vs 9.5%; P=NS; non-ST-elevation ACS (n=6,805): 9.7% vs 11.8%; P<0.05; noninvasive treatment approach (n=5,216): 12.0% ticagrelor vs 14.3% clopidogrel; P=0.04

Safety: invasive treatment approach: 11.5% ticagrelor vs 11.6% clopidogrel; P=0.88; noninvasive treatment approach: 11.9% ticagrelor vs 10.3% clopidogrel; P=0.08

Notes: 5All patients received aspirin; *primary end point in this subgroup analysis was CV death, MI, or urgent target-vessel revascularization within 30 days of PCI.

Abbreviations: ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; CURE, Clopidogrel in Unstable angina to prevent Recurrent Events; CV, cardiovascular; MI, myocardial infarction; CURRENT-OASIS 7, Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events – Seventh Organization to Assess Strategies in Ischemic Syndromes; STEMI, ST-elevation myocardial infarction; CLARITY-TIMI 28, Clopidogrel as Adjunctive Reperfusion Therapy – Thrombolysis in Myocardial Infarction 28; COMMIT, Clopidogrel and Metoprolol in Myocardial Infarction Trial; TRITON-TIMI 38, Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel – Thrombolysis in Myocardial Infarction 38; TRILGY-ACS, Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes; PLATO, Platelet Inhibition and Patient Outcomes; NS, not statistically significant; CABG, coronary artery bypass grafting.

Diabetes

Diabetes patients have been shown to have diminished responsiveness to clopidogrel, which is believed to be due to disease-mediated changes in drug pharmacokinetics that may involve reduced clopidogrel absorption and altered clopidogrel metabolism. While certainly not conclusive, there is some suggestion that patients with diabetes in large clinical trials receiving clopidogrel did not obtain as much benefit as patients without diabetes. For example, the 2.8% 7.9% of patients without diabetes demonstrated clinical benefit compared to those with diabetes in the TRET study (P=0.09). Prasugrel increased the risk of major bleeding by 3.9% in patients undergoing PCI due to an efficacy advantage over clopidogrel without PPCI, but the increased risk of bleeding with prasugrel has not been adequately studied in STEMI patients undergoing PCI.

Its use is more appropriately restricted to ACS patients undergoing PCI, especially patients with STEMI undergoing PCI. Due to an efficacy advantage over clopidogrel without PPCI, its use is more appropriately restricted to ACS patients with diabetes.
The antiplatelet effects of prasugrel are comparable in both diabetic and nondiabetic patients reported that smoking was not associated with an increased risk of intracranial hemorrhage. However, a large analysis of several patient cohorts reported that smoking was not associated with an enhanced platelet response to clopidogrel and clinical trial data have not convincingly proven that clopidogrel is more efficacious in smokers compared to nonsmokers. The antiplatelet effects of prasugrel are comparable in both smokers and nonsmokers, and prasugrel has been shown to elicit greater antiplatelet effects than clopidogrel regardless of smoking status. Prasugrel and clopidogrel were compared in a subanalysis of the TRILOGY-ACS trial to explore the relationship between smoking status, platelet reactivity and clinical outcomes. The 30-month analysis included 7,062 patients less than 75 years of age randomized to clopidogrel or prasugrel and evaluated clinical ischemic outcomes (cardiovascular death, MI, or stroke). Twenty-three percent of these patients (n=1,613) also had platelet function testing performed. In this study, current smokers had fewer comorbidities at baseline and nearly half quit smoking during follow-up. On-treatment platelet reactivity was lower with prasugrel compared to clopidogrel, but no significant interaction between smoking status and platelet reactivity was noted. The frequency of ischemic outcomes in smokers was significantly lower with prasugrel (11.7%) versus clopidogrel (18.6%), but no difference was observed in nonsmokers (13.8% vs 13.7%, respectively; P=0.002 for interaction). These findings are hypothesis generating but suggest a relationship between smoking and response to antiplatelet therapy with prasugrel. In the PLATO trial, the clinical benefits of ticagrelor were not affected by smoking status, with ticagrelor demonstrating a 17% reduction in risk of the primary end point compared to clopidogrel in smokers and an 11% reduction in risk in ex/nonsmokers (P=0.5).

Other considerations
Prasugrel is contraindicated in patients with prior stroke or transient ischemic attack since it was detrimental to these patients in the TRITON-TIMI 38 trial: there was a 54% increase in the risk of the combined end point of death, MI, stroke, or non-CABG-related major bleeding compared to clopidogrel (P=0.04), including more intracranial bleeds (2.3% prasugrel, 0% clopidogrel; P=0.02). TRITON-TIMI 38 also showed that prasugrel did not provide any efficacy benefit in patients at least 75 years of age or among patients who weighed less than 60 kg with a tendency toward more major bleeding, although this was not statistically significant (non-CABG-related major bleeding was 4.3% with prasugrel, 3.3% with clopidogrel; P=0.10). Patients over 75 years of age also had an increased risk of fatal and symptomatic intracranial bleeds with prasugrel therapy (1.0% and 0.8%, respectively, with prasugrel vs 0.1% and 0.3%, respectively, with clopidogrel). These findings have led to the recommendation to avoid prasugrel in patients 75 years of age or older unless the benefits are believed to outweigh the risks and to consider lowering the maintenance dosage from 10 mg daily to 5 mg daily in patients weighing less than 60 kg. Ticagrelor was associated with an increased risk of intracranial hemorrhage in the PLATO trial and as such is contraindicated in patients with a history of intracranial hemorrhage. Ticagrelor is also contraindicated in patients with severe hepatic impairment and is to be used cautiously in patients with moderate hepatic impairment due to both an increased risk of bleeding due to a reduction in the synthesis of coagulation proteins as well as a probable increase in ticagrelor exposure due to reduced hepatic metabolism.

Timing of therapy
Patients presenting with ACS often possess much uncertainty in terms of not only diagnosis but also the extent of coronary artery disease. This is especially true with non-ST-elevation ACS. Consequently, there may be reluctance to begin P2Y12 inhibitor therapy until coronary angiography has been performed and the coronary anatomy defined. The CREDO trial showed a reduction in the combined end point of death, MI, or urgent target-vessel revascularization when clopidogrel pretreatment (300 mg) was given more than 6 hours before
Pantoprazole is a potential alternative, especially if the delay to angiography will be several hours. If prasugrel is to be used and angiography is planned within hours of presentation, then prasugrel can be given once coronary anatomy is known and the decision has been made to undergo PCI.

Concomitant medications
Proton pump inhibitors
Proton pump inhibitors (PPIs) are substrates and inhibitors of CYP2C19, the same enzyme that plays a major role in clopidogrel activation. Concern therefore exists as to whether or not PPIs may interfere with the activation of clopidogrel and, hence, its pharmacologic effect. Several retrospective cohort studies and prospective randomized trials have evaluated the possible interaction between PPIs and clopidogrel. Some report a significantly increased risk (6%–18%) for negative cardiac-related outcomes and overall mortality (3%–9% increased risk) associated with concurrent use of PPIs and clopidogrel. In contrast, other clinical outcome studies have reported minimal or no impact of concurrent PPI and clopidogrel use on cardiovascular outcomes. The major study investigating this issue was the COGENT trial. This study randomized 3,873 patients with an indication for DAPT to receive aspirin with either clopidogrel plus omeprazole or clopidogrel plus placebo. The primary cardiovascular end point of the combination of cardiovascular death, MI, revascularization, or stroke occurred at similar rates in both groups (4.9% omeprazole vs 5.7% placebo; \( P=0.98 \)). While these results seem to suggest no clinically meaningful interaction between omeprazole and clopidogrel, the study was prematurely terminated due to lack of funding, which limits its power. Given the conflicting data, the potential for negative outcomes from concomitant use with clopidogrel, and the availability of suitable alternatives for PPI therapy, it is recommended to avoid omeprazole or esomeprazole (stronger inhibitors of CYP2C19) in patients treated with clopidogrel. Pantoprazole is a potential alternative PPI to use in patients taking clopidogrel who require a PPI. Pantoprazole is a weaker inhibitor of CYP2C19 and has less effect on the activity of clopidogrel. Neither prasugrel nor ticagrelor relies heavily on CYP2C19 for metabolism, and accordingly, neither of these drugs exhibit any significant interactions with PPIs. Aside from potentially interfering with clopidogrel activation, PPIs have been accused of increasing the risk of MI independent of antiplatelet therapy.
PPI use to be significantly associated with a higher risk of MI (HR 1.58, 95% CI 1.11–2.25; *P*=0.011). However, with a number needed to harm of 4,357, the benefits of PPI therapy may very well outweigh this potential risk for many patients.82

**Aspirin**

The PLATO trial demonstrated that patients enrolled in North American sites did not benefit as much from ticagrelor therapy as those outside of North America. In fact, there was even suggestion that clopidogrel may be better than ticagrelor in these patients. The HR for North American participants was 1.25 (95% CI 0.93–1.67) compared to 0.80–0.86 for the rest of the world.23 This led to a delay in the approval of ticagrelor in the United States pending an explanation for this phenomenon. Subsequent analysis of data from PLATO demonstrated that the use of aspirin dosages of 300 mg/day or greater was substantially higher in the United States (53.6% of patients) compared to the rest of the world (1.7% of patients). Of 37 different baseline and post-randomization factors explored, aspirin dosage was the only factor that was able to explain the geographic disparity in results.83

When the results were analyzed in patients taking low-dose (≤100 mg/day) aspirin, consistent benefit was seen with ticagrelor, even in North American patients.89 Consequently, the product labeling for ticagrelor prohibits the usage of this drug to patients taking daily aspirin dosages in excess of 100 mg daily.14 To date, there remains no clear explanation as to why higher doses of aspirin may mitigate the benefits of ticagrelor and neither prasugrel nor clopidogrel has shown this phenomenon. In an effort to better describe this interaction, there exist some theories as to why ticagrelor may interact with aspirin.84 One theory is that P2Y₁₂ inhibitors are somewhat reliant on prostacyclin for their antiplatelet effect and inhibiting prostacyclin with higher dosages of aspirin may therefore be counterproductive.85 Ticagrelor may be most susceptible to this interaction because of its relatively strong inhibition of P2Y₁₂. Another theory is that ticagrelor is unique from other P2Y₁₂ inhibitors in that it possesses off-target effects unrelated to platelet P2Y₁₂ inhibition that may be affected by aspirin. For example, ticagrelor has been shown to inhibit vasoconstriction by acting on vascular smooth muscle cell P2Y₁₂ receptors, an effect that was attenuated by higher but not lower doses of aspirin.84,85

**Oral anticoagulants**

Patients with ACS who have a need for oral anticoagulation (eg, atrial fibrillation, mechanical heart valve) represent a complicated treatment group. Logically, adding an antiplatelet medication to a patient taking an oral anticoagulant presents an increased bleeding risk.86,87 Clinical practice guidelines address this issue, but the deficiency of controlled clinical trials in this area makes it difficult to establish definitive recommendations. The WOEST trial was a randomized, open-label study comparing the safety and efficacy of clopidogrel alone and clopidogrel plus aspirin in 573 patients undergoing PCI who also had an indication for oral anticoagulation (69% atrial fibrillation, 10%–11% mechanical valve).88 The oral anticoagulant used was warfarin or a warfarin-like drug. After 1 year of treatment, the primary end point of any bleeding episode within 1 year of PCI occurred in 19.4% of patients receiving double therapy and 44.4% of patients receiving triple therapy (HR 0.36, 95% CI 0.26–0.50; *P*<0.0001). The combined secondary end point of death, MI, stroke, target-vessel revascularization, and stent thrombosis occurred in 11.1% of patients receiving double therapy and 17.6% of patients receiving triple therapy (*P*=0.025).

While underpowered to detect a significant effect on cardiovascular outcomes, the WOEST trial did provide enough evidence to prompt some clinicians to omit aspirin from a post-stent regimen in patients in need of oral anticoagulation. This treatment approach is reflected as a Class IIb recommendation (benefit ≥ risk; treatment may be considered) in current guidelines for managing atrial fibrillation.89 These same guidelines as well as others also mention using a bare-metal stent, when appropriate, over a drug-eluting stent as a means of minimizing the duration of DAPT in patients needing triple antithrombotic therapy or who are at a high bleeding risk.5,16,90 Current clinical practice guidelines (most released before the publication of WOEST) neither discourage nor condone triple antithrombotic therapy,5,58 although guidelines from the European Society of Cardiology as well as the American College of Chest Physicians (both published prior to WOEST) are in favor of triple therapy in patients with atrial fibrillation and a CHADS2 or CHADS2-VASc score of ≥2.59,90 The American College of Chest Physicians recommend triple antithrombotic therapy for 1 month for a bare-metal stent and 3–6 months following drug-eluting stent placement, followed by discontinuation of the P2Y₁₂ inhibitor.90

Clearly, more research is needed to help guide the clinician in managing the post-ACS patient with a need for oral anticoagulation. While most clinical practice guidelines are rather neutral in their recommendations, there are guidelines that are in favor of triple antithrombotic therapy in this situation. However, the evidence that is available would
suggest using clopidogrel as the P2Y\textsubscript{12} inhibitor of choice and warfarin (or warfarin-like compound) as the oral anti-coagulant of choice should triple antithrombotic therapy be employed. This decision has to be made weighing the risks and benefits in each individual patient.

**Personalized therapy**

**Platelet function testing**

The reported incidence of patients with high platelet reactivity (HPR) while taking clopidogrel is reported to be between 4% and 30%\textsuperscript{91–94} Five meta-analyses of prospective observational studies and subanalyses of randomized controlled studies involving >10,000 PCI patients have reported strong associations between HPR while on clopidogrel and adverse cardiovascular outcomes.\textsuperscript{95–99} Strategies have been tested to overcome poor responsiveness to clopidogrel, including increasing the clopidogrel dose or switching to a more potent P2Y\textsubscript{12} inhibitor.

The Gauging Responsiveness with A VerifyNow assay – Impact on Thrombosis and Safety (GRAVITAS) study was the first large randomized prospective trial evaluating the clinical benefit of tailored clopidogrel treatment in patients undergoing PCI.\textsuperscript{100} GRAVITAS included 2,214 patients, most with stable coronary artery disease, who received a 600 mg clopidogrel loading dose before PCI with stent implantation. At 12–24 hours after PCI, patients receiving clopidogrel with HPR (defined as P2Y\textsubscript{12} reaction units [PRU] \(\geq 230\) with VerifyNow P2Y\textsubscript{12}) were randomized to standard clopidogrel dosing (75 mg daily) or high-dose clopidogrel (150 mg daily). At 6 months, there was no difference in the primary composite efficacy end point of cardiovascular death, acute MI, or stent thrombosis (2.3% in both groups; \(P=0.97\)). There was also no difference in the primary safety end point of severe or moderate bleeding based on the GUSTO definition (1.4% high dose vs 2.3% standard dose; \(P=0.1\)). Criticisms of the GRAVITAS trial include an event rate much lower than expected, possibly causing the trial to be underpowered to detect a difference between treatments. Additionally, the threshold of PRU \(\geq 230\) to classify poor responders may have been too high. A post hoc analysis identified PRU \(\geq 208\) as being a more predictive cutoff value for greater risk of ischemic events.\textsuperscript{101} In this analysis, achieving an on-treatment PRU <208 was associated with a lower risk of cardiovascular events at both 2 months and 6 months whereas achieving a PRU <230 was not. In addition, increasing the clopidogrel dose to 150 mg was not sufficient to overcome a poor response to clopidogrel in many patients in the tailored treatment arm, as 36%–40% of patients remained poor (PRU \(\geq 230\)) responders when platelet function testing was repeated at 1 month and 6 months.\textsuperscript{100} The ARCTIC trial evaluated the clinical utility of platelet function testing (using VerifyNow P2Y\textsubscript{12}) to adjust antiplatelet regimens for patients scheduled for PCI.\textsuperscript{102} This study randomized 2,440 patients to receive adjusted antiplatelet treatment based on platelet function testing compared with conventional antiplatelet dosing. One-third of patients in the monitoring group had HPR on clopidogrel (PRU \(\geq 235\)) and received adjusted antiplatelet therapy with either high-dose clopidogrel or prasugrel. Platelet function testing was repeated at 14 days and 30 days after stent implantation, with further adjustments made in therapy. After 1 year of follow-up, there was no difference in the primary composite end point of death, MI, stroke/transient ischemic attack, urgent coronary revascularization, and stent thrombosis between the group who received platelet function monitoring compared with the group who had not received monitoring (34.6% vs 31.1%; \(P=0.10\)). There was also no difference in major bleeding (2.3% [monitored group] vs 3.3%; \(P=0.15\)). This study showed no benefit in adjusting platelet therapy based on platelet function testing.

While ARCTIC and GRAVITAS evaluated increasing the dosage of clopidogrel based on platelet function testing, the TRIGGER PCI trial sought to determine if prasugrel offered any benefit to patients with stable angina receiving a drug-eluting stent who were identified as poor clopidogrel responders. Poor responders to clopidogrel (PRU \(>208\) with VerifyNow P2Y\textsubscript{12}) were randomized to either 75 mg clopidogrel or 10 mg prasugrel daily starting the morning after PCI. The trial was stopped for futility after enrollment of only 423 patients because of low 6-month major adverse cardiovascular event rates (0.5% in the clopidogrel arm and 0% in the prasugrel arm).\textsuperscript{103} In summary, the three largest studies evaluating changing antiplatelet therapy in poor responders based on platelet function testing have failed to show benefit with respect to clinical outcomes.

The TRILOGY-ACS platelet function substudy investigated the relationship between platelet function testing and clinical outcomes in 2,564 patients with ACS who were medically managed without revascularization and randomized in the TRILOGY-ACS trial to receive either prasugrel or clopidogrel in addition to aspirin therapy.\textsuperscript{104} Platelet function testing was performed at baseline, at 2 hours, and at 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, and 30 months after randomization using the VerifyNow P2Y\textsubscript{12} test. Prasugrel provided a greater antiplatelet effect than clopidogrel at all time points, as evidenced by lower PRU. At 30 months, the primary composite efficacy end point
of cardiovascular death, MI, or stroke was 17.2% in the prasugrel group and 18.9% in clopidogrel group (P=0.29). There was also no significant correlation between PRU value and presence or absence of primary efficacy event rate. Overall, this trial found that medically managed ACS patients treated with prasugrel have lower platelet reactivity than patients treated with clopidogrel, but this was not associated with a difference in ischemic outcomes. In addition to potentially being underpowered, this study assessed PRU at 2 hours, well before steady-state drug concentrations are achieved, and correlated this PRU with clinical events occurring out to 5 days. Thus, early clinical events were being attributed to a time period during which the drug did not exert its maximal effect. In addition to adjusting P2Y12 inhibitor therapy to decrease ischemic events, there is also potential to adjust therapy to decrease bleeding events. In the TRITON-TIMI 38 and PLATO trials, the use of prasugrel or ticagrelor was associated with a higher rate of bleeding than with clopidogrel.22,23 Dosage adjustments based on platelet measurements may be able to prevent bleeding by avoiding excessive platelet inhibition, but has yet to be fully investigated. There are several platelet function tests available with different methodologies. In selecting a test that will be useful in clinical practice for P2Y12 inhibitors, it should be simple to perform; have rapid, highly reproducible results; be cost-effective; and provide meaningful prognostic or treatment course information. For P2Y12 inhibitor therapy, it would be best to use a platelet function test that directly measures ADP-stimulated activity. There are currently four ADP-stimulated assays (light transmission aggregometry, Multiplate, vasodilator-stimulated phosphoprotein [VASP], and VerifyNow P2Y12) that were shown to predict clinical outcomes in patients after PCI. Light transmission aggregometry has poor standardization, and VASP has a cumbersome testing process; thus, VerifyNow P2Y12 or Multiplate would seem to be the most preferable tests. There is also a discrepancy for the ideal cutoff level in terms of whether a PRU of >208 or >235 is more acceptable to define poor response to antiplatelet therapy. Additionally, the ideal time to perform platelet function testing after initiation of drug therapy is unknown. A complete discussion of platelet function tests is beyond the scope of this article, but has recently been reviewed elsewhere.

There are several drawbacks to tailored antiplatelet treatment using platelet function testing, including cost, availability of tests, increased workload, and lack of universal agreement on cutoff values to define poor response to antiplatelet therapy. More importantly, however, trials that have studied alternative regimens for patients with HPR, ie, increasing clopidogrel dosage or changing to another P2Y12 inhibitor, have not convincingly shown benefits of such strategies. As such, there is uncertainty as to how to proceed with a patient who demonstrates HPR while on clopidogrel. Given this uncertainty, current guidelines do not recommend the use of routine platelet function testing as an HPR screening tool for patients on clopidogrel. However, they do allow the clinician leeway in performing such testing in patients considered high risk for poor clinical outcomes, such as patients undergoing high-risk PCI procedures (eg, treatment of extensive and/or very complex disease). Should platelet function testing show HPR while these patients are on clopidogrel therapy, some providers would desire a switch to either prasugrel or ticagrelor even in the absence of data demonstrating a convincing clinical benefit with such a strategy. Some would discourage such practice claiming that “[…] no treatment with proven efficacy and safety should be replaced by new treatments, even if theoretically more rational, prior to demonstration of their efficacy, safety and favourable cost–benefit ratio.” Others would argue that the likelihood of harm of switching from clopidogrel to another P2Y12 inhibitor in a patient not at high risk for bleeding is low and that given the limitations of current studies, the benefit of such a switch simply has not been realized in a clinical trial setting. Given these considerations, testing for HPR while on clopidogrel and adjusting therapy based on these results is not currently recommended for all patients but is not an unreasonable course of action for high-risk patients.

Genetic testing
Clopidogrel is a prodrug that requires two-step oxidative metabolism by the CYP system to be converted into its active form (Figure 2). Carriers of CYP2C19 loss-of-function alleles have reduced activity of the enzyme necessary for clopidogrel activation. The prevalence of poor-metabolizer genotypes varies by race. Reported ranges for poor-metabolizer genotypes are from 20% to 30% in White individuals, from 30% to 45% in African American individuals, and up to 50%–65% in East Asians. In 2010, the US Food and Drug Administration (FDA) added a boxed warning to the label of clopidogrel, including a reference to patients who do not effectively metabolize the drug, and therefore may not receive its full clinical benefits based on their genetic composition. There have been discrepancies in the evidence linking the CYP2C19 loss-of-function allele to an increased risk of cardiovascular events. Early trials reporting a strong association between CYP2C19 loss-of-function alleles and...
Clopidogrel metabolism.

Notes: Clopidogrel is a prodrug that requires two metabolic steps in order to convert it to its active form. Genetic polymorphisms in the CYP2C19 enzyme (shown in blue font), affect both of these steps and, hence, the pharmacodynamic effect of clopidogrel.

Figures 2

Clopidogrel metabolism.

Notes: Clopidogrel is a prodrug that requires two metabolic steps in order to convert it to its active form. Genetic polymorphisms in the CYP2C19 enzyme (shown in blue font), affect both of these steps and, hence, the pharmacodynamic effect of clopidogrel.

Poor cardiovascular outcomes are thought to have overemphasized the effect of loss-of-function CYP mutations and clinical outcomes with clopidogrel due to bias and population diversity.\textsuperscript{131–134} Two more recent meta-analyses did not indicate substantial influence of the presence of CYP2C19 loss-of-function alleles on major adverse cardiac events in patients taking clopidogrel.\textsuperscript{135,136} The \textit{ABCB1} gene is an additional variant that has been shown to impact clopidogrel efficacy. \textit{ABCB1} encodes for P-glycoprotein efflux pumps, which decrease drug absorption. Patients with high expression of \textit{ABCB1} have reduced concentrations of active clopidogrel metabolite\textsuperscript{137} and increased rates of cardiovascular events.\textsuperscript{138} Prasugrel undergoes rapid intestinal and serum metabolism to an intermediate that is subsequently converted to an active metabolite primarily by not only CYP3A4 and CYP2B6 but also by CYP2C19, CYP2C9, and CYP2D6.\textsuperscript{139–141} Cuisset et al evaluated the effect of CYP2C19 genetic variants on response to prasugrel and found that carriers of the loss-of-function CYP2C19*2 allele had a higher rate of HPR than noncarriers (16% vs 4%; \textit{P}=0.01), a factor that increases the risk for major adverse cardiovascular events.\textsuperscript{142} This is somewhat in contrast to the RESET GENE trial, a crossover study in which 32 patients with HPR on 75 mg clopidogrel received either high-dose clopidogrel (150 mg daily) or prasugrel (10 mg daily) for 2 weeks.\textsuperscript{143} In this study, there were few CYP2C19*2 noncarriers who exhibited HPR on either therapy (12.5% had HPR on clopidogrel, 0% on prasugrel; \textit{P}=0.274), but a significant difference was seen in the percentage of CYP2C19*2 carriers exhibiting HPR while on high-dose clopidogrel (43.7%) versus prasugrel (0%; \textit{P}=0.003).\textsuperscript{143} A genetic substudy of TRITON-TIMI 38 evaluated if reduced function CYP alleles were associated with adverse cardiovascular outcomes in a cohort of 1,466 subjects allocated to prasugrel.\textsuperscript{124} This analysis found no significant associations between any of the 54 tested CYP genotype alleles and the composite end point of cardiovascular death, MI, or stroke or any of these individual end points. Another analysis of 1,461 patient taking prasugrel in TRITON-TIMI 38 evaluated the impact of \textit{ABCB1} and found no significant association between \textit{ABCB1} genotype and clinical outcomes.\textsuperscript{144} While clopidogrel and prasugrel both require metabolism to be activated, only about 15% of a given clopidogrel dose is available for activation since the majority of clopidogrel is converted to an inactive metabolite (Figure 2). This is in contrast to prasugrel, which does not have a known inactive metabolite, leaving the majority of a given dose available.
for metabolic activation. Since clopidogrel has less substrate for enzymatic activation, it may be more reliant on such activation for its pharmacologic effect, making it potentially more sensitive to CYP2C19 and ABCB1 mutations than prasugrel.

Alexopoulos et al compared the relative antiplatelet effects of high-dose clopidogrel and prasugrel in a randomized, crossover trial enrolling 71 post-PCI patients with HPR (PRU ≥235 with VerifyNow P2Y12). Patients received a clopidogrel loading dose prior to PCI, and platelet reactivity was measured 24 hours after the procedure to determine HPR. Patients were then randomized to 150 mg/day of clopidogrel or prasugrel with platelet function testing performed 30 days later, at which time patients were crossed over to receive the alternative regimen. After 30 days, platelet reactivity was significantly lower in patients treated with prasugrel than those with clopidogrel (129.4 PRU vs 201.7 PRU; \( P < 0.001 \)). Of note, the difference in magnitude of platelet function suppression between prasugrel and clopidogrel was greater in patients with >1 loss-of-function CYP2C19 allele (122.9 mean PRU difference) than those without any loss-of-function alleles (47.5 mean PRU difference). The rates of HPR were also lower with prasugrel versus clopidogrel in both carriers and noncarriers of a CYP2C19 loss-of-function allele. This study demonstrated prasugrel to be a more viable option than high-dose clopidogrel for PCI patients with HPR while on standard clopidogrel therapy.

Ticagrelor does not require hepatic metabolism for activation. The main metabolite of ticagrelor is also active and makes up 30%-40% of the plasma concentration of ticagrelor. An analysis of 174 patients enrolled in the ONSET/OFFSET and RESPOND studies who underwent genetic testing showed lower platelet reactivity with ticagrelor compared to clopidogrel regardless of CYP2C19 genotype. A genetic analysis of 10,285 patients from the PLATO trial found that patients with high expression of ABCB1 or a CYP2C19 loss-of-function allele had a nonsignificant trend toward better outcomes with ticagrelor. For patients with high expression of ABCB1, event rates for the composite outcome of cardiovascular death, MI, or stroke were 8.8% with ticagrelor vs 11.9% with clopidogrel (\( P = 0.01 \)). In patients with a CYP2C19 loss-of-function allele, the event rate with ticagrelor was 8.6% versus 11.2% with clopidogrel (\( P = 0.038 \)). In the clopidogrel group, the event rate at 30 days was higher in patients with a loss-of-function CYP2C19 allele compared to those without a loss-of-function allele (5.7% vs 3.8%, \( P = 0.028 \)). Not unexpectedly, the event rate in patients receiving ticagrelor was the same in those with and without CYP2C19 loss-of-function alleles.

Given the potential increased risk of events in patients who are poor clopidogrel metabolizers, there have been investigations into solutions to overcome or circumvent this pathway. Several studies have demonstrated that increasing the clopidogrel dosage does not completely overcome the variability in platelet inhibition. The utility of prasugrel in CYP2C19*2 carriers was assessed by the RAPID GENE trial, which randomized patients undergoing PCI for ACS or stable angina to rapid point-of-care genotyping (n=91) or standard treatment (n=96). Patients in the rapid genotyping group were screened for the CYP2C19*2 allele. If present, 10 mg prasugrel daily was given and if absent, then 75 mg/day of clopidogrel was given, which was also the treatment given to patients in the standard treatment group. The primary end point was the proportion of CYP2C19*2 carriers with HPR (VerifyNow P2Y12 PRU value >234) after 1 week. The CYP2C19*2 allele was present in 23 individuals in each group (genotyping and standard care). None of the CYP2C19*2 carriers receiving prasugrel in the genotyping group had HPR after 1 week of treatment compared to seven (30%) of the CYP2C19*2 carriers allocated to standard clopidogrel treatment (\( P = 0.009 \)).

The RAPID GENE trial was small, and while it indicated that genotyping can identify many patients with poor response to clopidogrel, there are genetic and environmental factors that also affect platelet inhibition. It is estimated that the CYP2C19 allele explains only about 10% of the variation in platelet response. Therefore, it is unlikely that genetic testing alone would give an adequate picture of a patient’s likeliness to have sufficient platelet inhibition with clopidogrel or guide a therapeutic strategy. Previously, genetic testing was limited by long turnaround time for results. However, now two point-of-care CYP2C19 tests, the Spartan RX (Spartan Bioscience Inc., Ottawa, ON, Canada) and Verigene (Nanosphere, Inc., Northbrook, IL, USA), identify loss-of-function CYP2C19*2 and *3 alleles. The differences between the two systems are that Verigene uses whole blood and can genotype several CYP2C19 variants, whereas Spartan uses a buccal swab and can detect only the *2, *3, and *17 variants. The time to get results is also shorter for the Spartan system (1 hour vs 3 hours). Despite the technical improvements over the years, genetic testing is still expensive and often not covered by insurance companies, which limits its use. However, the main factor limiting the use of genetic testing for antiplatelet therapy is conclusive
evidence of efficacy and safety of tailoring regimens based on genetic information. Owing to this lack of outcome data, current clinical practice guidelines for genetic testing mirror those for platelet function testing: it is not recommended for routing screening, but a clinician may opt to perform testing for CYP2C19 loss-of-function alleles in patients at high risk for poor clinical outcomes with the caveat that it is relatively unknown how to proceed with that information.3,119

Cost

Cost is a major factor that compounds the decision of which P2Y12 inhibitor to use. While clopidogrel is available generically and is less expensive than prasugrel or ticagrelor, these newer agents have been shown to be more effective than clopidogrel at reducing the risk of cardiovascular events in most subsets of patients. Thus, the cost of the medication is not the only consideration, as the costs of recurrent event rates must also be brought into the equation.

Crespin et al performed a cost-effectiveness analysis to estimate the 5-year medical costs and outcomes for a cohort of 100,000 ACS patients enrolled in Medicare receiving either: 1) genotype-driven or 2) ticagrelor-only treatment.160 With genotype-driven therapy, patients received clopidogrel unless they had a CYP2C19*2 mutation, in which event they received ticagrelor. Data comparing the clinical performance of ticagrelor and clopidogrel were derived from PLATO for the first 12 months of therapy. After 12 months, event rates were assumed to be equal for ticagrelor and clopidogrel treatment. Both bleeding risk and cardiovascular event rates were included. Outcomes were life years and quality-adjusted life years (QALYs) gained. Costs assumed in this study were $200 for genotyping and $30 and $164 for a 1-month supply of clopidogrel and ticagrelor, respectively. Results yielded a favorable result for universal ticagrelor. After 5 years of therapy, the incremental cost-effectiveness ratio (ICER) for universal ticagrelor was $10,059 per QALY versus genotype-driven treatment. The conclusion from this analysis was that prescribing ticagrelor universally increases QALYs for ACS patients at a cost below the typically accepted threshold for a cost-effective treatment (<$50,000 per QALY). This model had several limitations. The first was that the event rate in patients stratified to clopidogrel in the genotype-directed therapy was based on a modeled estimate and not actual rates observed in a clinical trial. An additional limitation of the trial is the cost calculation for ticagrelor of $164/month, which is only half of the current average wholesale price in the United States.

A similar analysis by Reese et al used a simulated cohort of patients with ACS undergoing PCI and evaluated results of patients receiving either: 1) genotype-guided therapy, 2) clopidogrel-only therapy, or 3) prasugrel-only therapy.161 In the genotype-guided strategy, patients with at least one CYP2C19 loss-of-function allele received prasugrel and patients with two functional CYP2C19 alleles received clopidogrel. The 15-month analysis examined the end points of a cardiovascular event, a bleeding event, or no event. This analysis based event probabilities on the TRITON-TIMI 38 trial, which included a genetic substudy. Drug cost estimates in this analysis for a 1-month supply of generic clopidogrel and prasugrel were $30 and $186, respectively. This study found that genotype-driven therapy was less costly compared to prasugrel for all patients (ICER: −$27,160) but was not less costly compared with clopidogrel for all patients (ICER: $2,300). An advantage of this study over Crespin et al is that it used genetically determined data. A limitation of this model was that the prasugrel price used in the study was half of the current average wholesale price of prasugrel in the United States.

The above trials suggest that ticagrelor is more cost-effective than genotype-driven therapy, but clopidogrel was more cost-effective than genotype-driven therapy or prasugrel therapy. The conclusions of these analyses, however, are dependent on a number of assumptions that are used in building these models. Also, the cost-effectiveness of these agents depends not only on their rates of effectiveness but also on their direct cost. Both ticagrelor and prasugrel will not be available generically for several years, while there are multiple generic manufacturers of clopidogrel. This will likely cause increased divergence in cost over time, which will need to be considered in selecting an agent.

The desire to use the most effective P2Y12 inhibitor while keeping drug costs at a minimum has led many clinicians to consider beginning a patient on either ticagrelor or prasugrel and then switching over to clopidogrel at a later time. The use of a more potent platelet inhibitor, such as prasugrel or ticagrelor, in the early stages of an ACS may provide more benefit at a time when countering enhanced platelet activation and aggregation is most important. Once this acute phase has passed, switching to a less powerful but more affordable agent (clopidogrel) would perhaps come without loss of clinical efficacy outside of the acute phase and lower the risk of bleeding over the long-term. However, Kerneis et al demonstrated that switching from prasugrel to clopidogrel after 15 days increased on-treatment platelet reactivity in 300 ACS patients.162 This trial was not designed to assess clinical outcomes, and as such, no
conclusions can be drawn in this regard. Similarly, the POBA SWITCH study involving 20 patients with ACS and very low platelet reactivity while on prasugrel (measured by VASP) demonstrated an increase in platelet reactivity when switched to clopidogrel after 1 month. However, after the switch, most patients still maintained a level of platelet inhibition that may be considered acceptable (ie, VASP platelet reactivity index <50%). The ongoing SWAP-4 trial (ClinicalTrials.gov Identifier: NCT02287909) is investigating the switch from ticagrelor to clopidogrel. Unfortunately, this is also a pharmacodynamic rather than a clinical trial. Larger, outcome-driven trials are needed before the practice of switching P2Y$_{12}$ inhibitors can be recommended.

**Conclusion**

Over the last 2 decades, there has been considerable evolution in antiplatelet therapies for ACS. In addition to aspirin, oral P2Y$_{12}$ inhibitors have proven efficacious in reducing recurrent cardiovascular events. Initially, P2Y$_{12}$ inhibition was primarily achieved with clopidogrel followed by the development, study, and use of the more potent P2Y$_{12}$ inhibitors, prasugrel and ticagrelor. While prasugrel and ticagrelor are more efficacious compared to clopidogrel, this comes at the risk of increased bleeding, which can be of significant clinical consequence. Many factors need to be weighed when choosing an optimal DAPT regimen taking into account patient-specific characteristics, comorbidities, concomitant medication use, and cost. More individualized assessment of platelet reactivity and pharmacogenetics offers promise in guiding drug selection, but incorporating this information into clinical practice has been elusive to date. Intravenous canagrelor offers the advantage of a quick onset and offset of drug effect, but its role in ACS treatment is currently rather limited. As our understanding of ACS continues to evolve, there remains much to learn with respect to optimizing the use of these powerful drugs to most effectively help achieve the best clinical outcomes.

**Disclosure**

The authors have no conflicts of interest to disclose.

**References**

15. Effient® (prasugrel) tablets, for oral use [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2013.


